Galmed Pharmaceuticals Ltd. (EOCN): R&D Expense
$4.87M
Year ended 2025-12-31
-27.9%
3-year compound annual growth
-28.5%
5-year compound annual growth
-4.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.87M | +63.6% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $2.98M | -16.5% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $3.57M | -72.5% | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $12.99M | -52.3% | 2025-04-02, From 2022-01-01 |
| 2021-12-31 | $27.22M | +4.4% | 2024-04-04, From 2021-01-01 |
| 2020-12-31 | $26.08M | +43.5% | 2023-03-29, From 2020-01-01 |
| 2019-12-31 | $18.18M | +118.7% | 2022-05-02, From 2019-01-01 |
| 2018-12-31 | $8.31M | -13.9% | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | $9.65M | -32.4% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $14.27M | +87.1% | 2019-03-13, From 2016-01-01 |
| 2015-12-31 | $7.63M | +14.5% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $6.66M | -7.5% | 2017-03-23, From 2014-01-01 |
| 2013-12-31 | $7.21M | +195.0% | 2016-03-22, From 2013-01-01 |
| 2012-12-31 | $2.44M | n/a | 2015-03-31, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd. (EOCN) | 2025-12-31 | $4.87M | +63.6% |
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $3.92M | -76.3% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Genelux Corp (GNLX) | 2025-12-31 | $19.85M | +4.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| Clene Inc. (CLNN) | 2025-12-31 | $14.01M | -30.1% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $14.29M | -60.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $7.95M | -29.9% |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $223.7K | -9.8% |
Compare EOCN, LITS, ALLR, GNLX side by side · Screen every company in Pharmaceutical Preparations ↗